The University of Tokyo's IPC has made a strategic investment of approximately 100 million yen into Crewt Medical Systems, a venture focusing on advanced medical devices for glaucoma screening.

Target Company Overview

Crewt Medical Systems Inc., headquartered in Shinjuku, Tokyo, is a venture established in 2013 by President Tetsuya Eguchi, who has an extensive background in medical device planning, development, regulatory affairs, and sales at HOYA Corporation. Crewt Medical Systems specializes in developing and marketing advanced medical equipment, notably the first head-mounted perimeter device, "Aimo," which is essential for glaucoma screening.

Glaucoma is the leading cause of blindness in Japan, affecting an estimated 4 to 5 million potential patients. Despite this, only about 1 million are undergoing treatment due to a lack of noticeable symptoms and convenient screening methods. The Aimo device addresses significant challenges in traditional perimeter testing, such as the need for a dark room, sequential examination of each eye, and lengthy procedures.

Industry Overview in Japan

The medical device industry in Japan is robust, characterized by a blend of innovative startups and established multinational corporations. Given the aging population, the demand for advanced medical technolo